Hadassah

Hadassah Researchers Identify Connection Between National Killer Cell and Cirrhosis

Tuesday, Mar 19 2013

Researchers at the Hadassah University Medical Center have discovered that over expression of an immune system Natural Killer (NK) cell called Neuroligin 4 can trigger cirrhosis of the liver by preventing the body from combating scarring. The Hadassah study compared blood samples from dozens of patients with cirrhosis to those of a healthy control group. "In their healthy form, the Neuroligin cells kill the scar-tissue cells," reports Prof. Rifaat Safadi, head of Hadassah's Liver Unit and this study. In the over expression scenario, he explains, "a mechanism is put into operation that keeps the cells from doing their unscarring work."

Several years ago, the same research team found that intact NK cells are good for the liver and prevent cirrhosis. The finding was published in the February 2006 issue of The Journal of Hepatology and also reported by a group of researchers at the National Institutes of Health in the United States. Next, Hadassah's researchers plan to investigate whether mutations of Neuroligin 4 also increase the risk of cirrhosis.

Hadasit, Hadassah's Technology Transfer Company, has already patented Neuroligin 4 in hopes of using it to develop treatments to fend off liver disease.


Read the story in Haaretz here>>

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, May 23 2018

From Legacy to Innovation: The Vision of Hadassah’s New Division of Nursing Director

Rely Alon, PhD, the new director of the Hadassah Medical Organization’s Division of Nursing and Health Professions, has a vision: “to bring Hadassah’s nurses to the forefront of leadership and to the spearhead of nursing in Israel.”

READ MORE ›
alt_text

Monday, May 7 2018

Hadassah Cardiac Specialists Are Collaborating with Colleagues to Save Syrian Children

In an effort to save the lives of Syrian children suffering from life-threatening and complex heart abnormalities, the Hadassah Medical Organization and the Baruch Padeh Medical Center in Poriya-Tiberias have launched a unique collaboration as part of the Israel Defense Forces’ Good Neighbor program.

READ MORE ›
alt_text

Monday, May 7 2018

Pluristem Stem Cell Therapy, Based on Hadassah Preclinical Research, Has Been Cleared by FDA

Pluristem Therapeutics has announced that its new cell therapy to treat acute radiation syndrome (PLX-R18), based on the pioneering studies performed within the laboratory of Prof. Raphael Gorodetsky at the Hadassah Medical Organization, has received clearance from the United States Food and Drug Administration to treat individuals who may have been acutely exposed to high-dose radiation as the result of a nuclear attack or accident.

READ MORE ›
alt_text

Thursday, May 3 2018

HMO Exclusive Call with Nurse Rely Alon

Please join us for an exclusive conference call with Dr. Rely Alon, Director, Division of Nursing & Health Professions, Wednesday May 9, 2018 from 10:00 - 11:00 am EDT

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More